UFP Technologies Inc. filings document operating results and material events for its medical-device contract development and manufacturing business. Form 8-K reports furnish quarterly and annual earnings releases, non-GAAP financial measures, Regulation FD investor presentation materials, material definitive agreements with strategic medical customers, cybersecurity incident disclosures, and executive succession and compensation arrangements.
Proxy filings cover board elections, executive compensation, equity awards, pay-versus-performance disclosure, and shareholder voting matters. These records frame the company's governance, capital and incentive structure, customer-contract disclosures, and public reporting obligations as a Nasdaq-listed operating company.
UFP Technologies (UFPT) reported that it issued a press release announcing financial results for the third quarter ended September 30, 2025. The press release is furnished as Exhibit 99.1 to this Form 8-K.
The company states that the information under Item 2.02, including Exhibit 99.1, is furnished and not deemed filed under the Exchange Act. The release includes forward-looking statements and a related cautionary note. UFPT’s common stock trades on The NASDAQ Stock Market L.L.C. under the symbol UFPT.
Daniel C. Croteau, a director of UFP Technologies, Inc. (UFPT), reported two open-market sales of common stock on 09/05/2025. The first sale reports 1,000 shares sold at $206.045 with 2,728 shares beneficially owned after that transaction. The second sale reports 1,873 shares sold at $206.00 with 855 shares beneficially owned after that transaction. The Form 4 was signed by an attorney-in-fact on 09/08/2025.
Form 144 notice for UFP Technologies Inc. (UFPT) shows a proposed sale of 2,873 shares of common stock through UBS Financial Services with an aggregate market value of $591,883. The shares represent part of the company's listed outstanding shares of 7,711,126 and the proposed approximate sale date is 09/05/2025 on NASDAQ.
The filing discloses the acquisition history for the shares to be sold: 1,318 shares were acquired by exercising options on 08/07/2025 (paid in cash), and the remainder came from vesting of stock unit awards on 05/31/2022 (610 shares), 05/31/2023 (647 shares), and 05/31/2024 (298 shares) with the awards treated as compensation. The filer reports no sales of issuer securities in the past three months.
UFP Technologies, Inc. filed a Form 8-K to furnish updated investor presentation materials under Regulation FD. The company attached the revised presentation as Exhibit 99.1, which it plans to use in meetings with investors, other interested parties, and in various speaking engagements. The materials are designated as furnished, not filed, meaning they are not subject to certain Exchange Act liabilities or automatically incorporated into other SEC filings. The company also notes that the presentation includes forward-looking statements and directs readers to the cautionary language in the slides regarding risks and uncertainties that could cause actual results to differ.
Daniel C. Croteau, a director of UFP Technologies, acquired 1,318 shares of common stock on 08/07/2025 at a reported price of $22.36 per share, increasing his direct beneficial ownership to 3,728 shares. The transaction corresponds to the exercise of a stock option with a $22.36 exercise price originally exercisable on 12/16/2015 and expiring on 12/16/2025. The Form 4 was signed by an attorney-in-fact on 08/14/2025.
UFP Technologies reported significant revenue and profit growth driven largely by recent acquisitions while facing margin pressure, higher interest expense, and customer concentration.
Net sales were $151.2 million for the quarter (up 37.2% year-over-year) and $299.3 million for the six months (up 39.1%). Net income was $17.2 million in the quarter and $34.4 million year-to-date, with diluted EPS of $2.21 for the quarter and $4.42 for six months. Gross margin declined to 28.8% in Q2 from 30.0% due to higher material, labor and onboarding inefficiencies at newly acquired AJR operations. SG&A rose in absolute dollars but decreased as a percentage of sales to 12.4% in Q2.
The company completed multiple acquisitions that expanded its medical-market capabilities and geography, including AJR Enterprises ($110.7M), AQF ($47.7M), Welch ($35.2M), Marble ($5.0M) and AJR Specialty ($2.8M); these collectively contributed about $76.3M in sales in H1 2025. Long-term debt outstanding was $163.6 million with Q2 interest expense of $2.7 million; cash from operations was $39.1 million for six months. Management disclosed contingent consideration obligations, tariff exposure estimated at ~$9 million annually, and customer concentration with two customers representing ~27.4% and ~20.3% of Q2 sales.